Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22504228 | 0.79 | PIK3C3 (0.33) | TRPM8TLR8MCHR1 | |
| SCHEMBL5321883 | 0.79 | TRPM8 (0.41) | MEN1POLBKMT2ATRPM8TLR8 | |
| SCHEMBL21994924 | 0.68 | TLR8 (0.34) | MEN1POLBKMT2ATLR8MCHR1 | |
| SCHEMBL21097265 | 0.67 | ALDH1A3 (0.34) | POLBKMT2A | |
| SCHEMBL1916331 | 0.67 | MEN1 (0.35) | MEN1POLBKMT2ATRPM8TLR8 | |
| SCHEMBL29333343 | 0.65 | P2RX3 (0.37) | POLBKMT2ATRPM8 | |
| SCHEMBL19523196 | 0.65 | P2RX3 (0.37) | KMT2ATRPM8 | |
| SCHEMBL10566894 | 0.65 | KMT2A (0.47) | POLBKMT2ATRPM8 | |
| SCHEMBL25910814 | 0.64 | P2RX3 (0.38) | POLB | |
| SCHEMBL10691443 | 0.64 | P2RX3 (0.36) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11697646-B2 | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11697646-B2 | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | LPAR3, LPAR1, LPAR2 | MEN1 3048/4885POLB 4089/4885KMT2A 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.